NasdaqGM:ORKABiotechs
Is Oruka’s Broadened IL-23 License Reshaping Optionality And Altering The Investment Case For Oruka Therapeutics (ORKA)?
In June 2026, Oruka Therapeutics, Inc. amended its IL-23 License Agreement with Paragon Therapeutics, expanding ORKA-001’s permitted uses to all therapeutic, prophylactic, palliative, and diagnostic applications, while imposing staged restrictions on clinical trial dosing for inflammatory bowel disease through 2030.
This broadened field, combined with conditional relaxation of certain limits following any material transaction or change of control, materially increases Oruka’s optionality in...